INDP – indaptus therapeutics, inc. (US:NASDAQ)

News

Indaptus Therapeutics (NASDAQ:INDP) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
Indaptus Therapeutics (NASDAQ:INDP) was upgraded by analysts at Wall Str
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
Indaptus Therapeutics GAAP EPS of -$2.98 [Seeking Alpha]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com